Table 5 Comparison of means for biochemical parameters by dual therapy combinations—DPP4I study, Anuradhapura 2017
Therapy | Investigations | |||||
|---|---|---|---|---|---|---|
No. of patients | HbA1C (%) | Pancreatic amylase (U/L) | Serum lipase (U/L) | AST (U/L) | ALT (U/L) | |
OOH group [mean (SD)] | ||||||
Metformin-glibenclamide | 14 | 9.3 (1.4) | 36.6 (19.2) | 42.3 (21.4) | 21.4 (8.2) | 21.6 (15.2) |
Metformin-gliclazide | 36 | 8.3 (1.5) | 39.7 (15.0) | 47.8 (16.1) | 23.7 (10.1) | 25.2 (17.8) |
Metformin SR-gliclazide | 12 | 8.8 (1.8) | 35.3 (10.5) | 48 (16.1) | 24.8 (8.5) | 26.5 (11.7) |
Metformin-gliclazide MR | 12 | 9.3 (2.0) | 53.8 (30.1) | 59.4 (21.0) | 29.4 (10.3) | 30 (16.4) |
Metformin SR-gliclazide MR | 04 | 9.4 (2.8) | 187.5 (309) | 51.5 (22.2) | 20.5 (3) | 23.3 (5.1) |
Metformin-glimepiride | 31 | 8.9 (2.2) | 38.2 (12.7) | 47.6 (16.5) | 24.7 (8.0) | 24.9 (10.8) |
Metformin SR-glimepiride | 09 | 8.4 (2) | 33.9 (11.9) | 50.2 (30.6) | 48.7 (56.9) | 36.2 (24.1) |
Metformin-tolbutamide | 04 | 8.1 (2.8) | 42 (11.3) | 52 (4.2) | 24.5 (3.5) | 25 (7.1) |
Metformin SR-tolbutamide | 01 | 8.2 | 63 | 52 | 17 | 12 |
DPP4I group [mean (SD)] | ||||||
Sitagliptin-metformin | 04 | 8 (1.4) | 74.5 (36.1) | 103.8 (54.1) | 26.5 (6.5) | 25 (7.2) |
Sitagliptin-gliclazide | 01 | 7.5 | 21 | 49 | 28 | 29 |
Sitagliptin-gliclazide MR | 01 | 7.9 | 59 | 125 | 23 | 24 |
Sitagliptin-glimepiride | 01 | 6.2 | 43 | 52 | 12 | 11 |